{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:17:31Z","timestamp":1761743851911,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["zefq-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.zefq.2023.10.004","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T05:51:39Z","timestamp":1700200299000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Epidemiology, comorbidity, and use of systemic therapies in patients with paediatric psoriasis in Germany"],"prefix":"10.1016","volume":"182-183","author":[{"given":"Mona","family":"Biermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9997","key":"10.1016\/j.zefq.2023.10.004_b0005","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.zefq.2023.10.004_b0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.04.139","article-title":"The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global Burden of Disease Study 2017","volume":"84","author":"Mehrmal","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.zefq.2023.10.004_b0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.zefq.2023.10.004_b0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.zefq.2023.10.004_b0025","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1007\/s12325-021-01795-7","article-title":"Real-world claims analyses of comorbidity burden, treatment pattern, healthcare resource utilization, and costs in pediatric psoriasis","volume":"38","author":"Edson-Heredia","year":"2021","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.zefq.2023.10.004_b0030","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/pde.13382","article-title":"Pediatric psoriasis: evolving perspectives","volume":"35","author":"Eichenfield","year":"2018","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.zefq.2023.10.004_b0035","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","article-title":"Psoriasis in children and adolescents: diagnosis, management and comorbidities","volume":"17","author":"Bronckers","year":"2015","journal-title":"Paediatr Drugs"},{"issue":"5","key":"10.1016\/j.zefq.2023.10.004_b0040","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2340\/00015555-2600","article-title":"Health-related quality of life in children and adolescents with psoriasis: a systematic review and meta-analysis","volume":"97","author":"Randa","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.zefq.2023.10.004_b0045","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/09546630902911847","article-title":"Epidemiology and prescribed treatments in childhood psoriasis: a survey among medical professionals","volume":"20","author":"De Jager","year":"2009","journal-title":"J Dermatol Treatment"},{"issue":"12","key":"10.1016\/j.zefq.2023.10.004_b0050","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archderm.141.12.1537","article-title":"Prevalence and treatment of psoriasis in the United Kingdom: a population-based study","volume":"141","author":"Gelfand","year":"2005","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.zefq.2023.10.004_b0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000381913","article-title":"Epidemiology and comorbidity in children with psoriasis and atopic eczema","volume":"231","author":"Augustin","year":"2015","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.zefq.2023.10.004_b0060","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2009.09593.x","article-title":"Epidemiology and comorbidity of psoriasis in children","volume":"162","author":"Augustin","year":"2010","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.zefq.2023.10.004_b0065","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/pde.12205","article-title":"Childhood psoriasis\u2014an analysis of German health insurance data","volume":"31","author":"Matusiewicz","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.zefq.2023.10.004_b0070","unstructured":"Augustin M, Glaeske G, Kh, Psoriasisreport. Pr\u00e4vention, Versorgung und Innovation; 2023."},{"issue":"2","key":"10.1016\/j.zefq.2023.10.004_b0075","first-page":"187","article-title":"Prevalence of psoriasis in children and adolescents in the united states: a claims-based analysis","volume":"17","author":"Paller","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"10.1016\/j.zefq.2023.10.004_b0080","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jamadermatol.2017.3029","article-title":"Safety of systemic agents for the treatment of pediatric psoriasis","volume":"153","author":"Bronckers","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.zefq.2023.10.004_b0085","article-title":"Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: a US and EU Real-world Evidence Study","volume":"102","author":"Seyger","year":"2021","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1016\/j.zefq.2023.10.004_b0090","series-title":"Databases for Pharmacoepidemiological Research","first-page":"125","article-title":"Institute for applied health research Berlin (InGef) DATABASE","author":"Andersohn","year":"2021"},{"key":"10.1016\/j.zefq.2023.10.004_b0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","article-title":"Sampling strategy, characteristics and representativeness of the InGef research database","volume":"206","author":"Ludwig","year":"2022","journal-title":"Public Health"},{"key":"10.1016\/j.zefq.2023.10.004_b0100","unstructured":"Federal Statistical Office, Population: Germany, cut-off date, age years; 2019. Available at, https:\/\/www-genesis.destatis.de\/genesis\/online\/link\/tabellen\/12411"},{"issue":"3","key":"10.1016\/j.zefq.2023.10.004_b0105","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10654-019-00500-x","article-title":"Guidelines and recommendations for ensuring Good Epidemiological Practice (GEP): a guideline developed by the German Society for Epidemiology","volume":"34","author":"Hoffmann","year":"2019","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"10.1016\/j.zefq.2023.10.004_b0110","first-page":"120","article-title":"Good Practice of Secondary Data Analysis (GPS): guidelines and recommendations","volume":"77","author":"Swart","year":"2015","journal-title":"Gesundheitswesen"},{"key":"10.1016\/j.zefq.2023.10.004_b0115","unstructured":"Schubert I, K\u00f6ster I. Routine data in healthcare handbook secondary data analysis: basics, methods and perspectives; 2014."},{"issue":"9","key":"10.1016\/j.zefq.2023.10.004_b0120","first-page":"959","article-title":"S2k guidelines for the treatment of psoriasis in children and adolescents \u2013 Short version part 2. JDDG","volume":"17","author":"Eisert","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"issue":"8","key":"10.1016\/j.zefq.2023.10.004_b0125","first-page":"856","article-title":"S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 1","volume":"17","author":"Eisert","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.zefq.2023.10.004_b0130","first-page":"m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ (Clin Res ed.)"},{"issue":"6","key":"10.1016\/j.zefq.2023.10.004_b0135","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2009.07.029","article-title":"Incidence of psoriasis in children: a population-based study","volume":"62","author":"Tollefson","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.zefq.2023.10.004_b0140","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/pde.12568","article-title":"Epidemiology of frequently occurring skin diseases in Italian children from 2006 to 2012: a retrospective, population-based study","volume":"32","author":"Cantarutti","year":"2015","journal-title":"Pediatr Dermatol"},{"issue":"7","key":"10.1016\/j.zefq.2023.10.004_b0145","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamadermatol.2017.0499","article-title":"Pediatric psoriasis comorbidity screening guidelines","volume":"153","author":"Osier","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.zefq.2023.10.004_b0150","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/pde.14208","article-title":"Pediatric psoriasis and association with cardiovascular and metabolic comorbidities: Systematic review and meta-analysis","volume":"37","author":"Phan","year":"2020","journal-title":"Pediatric Dermatol"},{"issue":"3","key":"10.1016\/j.zefq.2023.10.004_b0155","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"New England J Med"},{"issue":"2","key":"10.1016\/j.zefq.2023.10.004_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2015.09.056","article-title":"Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis","volume":"74","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.zefq.2023.10.004_b0165","doi-asserted-by":"crossref","first-page":"e13091","DOI":"10.1111\/dth.13091","article-title":"Adalimumab in severe plaque psoriasis of childhood: a multi-center, retrospective real-life study up to 52 weeks observation","volume":"32","author":"Di Lernia","year":"2019","journal-title":"Dermatol Ther"},{"issue":"10089","key":"10.1016\/j.zefq.2023.10.004_b0170","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.zefq.2023.10.004_b0175","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/bjd.18029","article-title":"Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study","volume":"181","author":"Tha\u00e7i","year":"2019","journal-title":"Brit J Dermatol"},{"issue":"8","key":"10.1016\/j.zefq.2023.10.004_b0180","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1468-3083.2012.04656.x","article-title":"Systemic steroids in the treatment of psoriasis: what is fact, what is fiction?","volume":"27","author":"Mrowietz","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.zefq.2023.10.004_b0185","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/jdv.14811","article-title":"Guideline-compliant prescription of biologicals and possible barriers in dermatological practices in Bavaria","volume":"32","author":"Schielein","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.zefq.2023.10.004_b0190","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3901","article-title":"Prescription behaviour and barriers to prescription of biologicals for treatment of chronic inflammatory skin diseases in dermatological practice in two German federal states","volume":"101","author":"Weiss","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.zefq.2023.10.004_b0195","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1346-8138.2011.01452.x","article-title":"Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic","volume":"39","author":"Kwon","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.zefq.2023.10.004_b0200","unstructured":"World Health Organization, Global report on psoriasis. 2016, Geneva: World Health Organization."},{"issue":"9","key":"10.1016\/j.zefq.2023.10.004_b0205","first-page":"1333","article-title":"Somatoform disorders","volume":"76","author":"Oyama","year":"2007","journal-title":"Am Fam Physician"}],"container-title":["Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1865921723001903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1865921723001903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T08:07:42Z","timestamp":1761725262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1865921723001903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":41,"alternative-id":["S1865921723001903"],"URL":"https:\/\/doi.org\/10.1016\/j.zefq.2023.10.004","relation":{},"ISSN":["1865-9217"],"issn-type":[{"type":"print","value":"1865-9217"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology, comorbidity, and use of systemic therapies in patients with paediatric psoriasis in Germany","name":"articletitle","label":"Article Title"},{"value":"Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.zefq.2023.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}